SMMT stock soars on NSCLC drug survival data beating Keytruda in China
- Posted on September 4, 2026
- By Bing News
- 0 Views
- 1 min read
In brief
Generating AI summary…
SMMT stock soars on NSCLC drug survival data beating Keytruda in China
Summit Therapeutics SMMT stock climbed 17.3% on Thursday after its Chinese partner Akeso reported positive overall survival (OS) results for ivonescimab in a head-to-head phase III study against Merck’s MRK blockbuster oncology drug, Keytruda (pembrolizumab), in certain patients with non-small cell lung cancer (NSCLC). The data provided fresh clinical validation for SMMT’s lead oncology candidate and increased investor focus on the drug’s...
